ストックスクリーナーアプリを入手
330.77
0.89%
2.92
前日終値:
$327.85
開ける：
$329.85
24時間の取引高:
499.46K
Relative Volume:
0.69
時価総額：
$23.28B
収益：
$2.36B
当期純損益:
$236.10M
株価収益率:
100.54
EPS:
3.29
ネットキャッシュフロー:
$382.50M
1週間 パフォーマンス:
+2.96%
1か月 パフォーマンス:
+15.83%
6か月 パフォーマンス:
+16.96%
1年 パフォーマンス:
+78.16%
1日の値動き範囲:
$328.08
$333.22
1週間の範囲:
$320.75
$334.18
52週間の値動き範囲:
$180.31
$334.18
Insulet Corporation Stock (PODD) Company Profile
PODD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
330.77 | 22.74B | 2.36B | 236.10M | 382.50M | 3.29 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-05-13 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-11-06 | 開始されました | Bernstein | Outperform |
| 2024-05-30 | 開始されました | Redburn Atlantic | Buy |
| 2024-05-07 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-21 | アップグレード | Citigroup | Neutral → Buy |
| 2023-08-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 開始されました | Wolfe Research | Peer Perform |
| 2022-11-04 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-07-28 | 開始されました | Wells Fargo | Overweight |
| 2020-04-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 開始されました | BofA/Merrill | Neutral |
| 2020-03-31 | ダウングレード | Berenberg | Buy → Hold |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-10 | 開始されました | CFRA | Sell |
| 2019-10-23 | 開始されました | Stifel | Hold |
| 2019-10-18 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-10-04 | ダウングレード | UBS | Buy → Neutral |
| 2019-10-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-06-10 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-04-20 | 開始されました | Berenberg | Buy |
| 2018-02-22 | 繰り返されました | Barclays | Overweight |
| 2018-01-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 開始されました | Barclays | Overweight |
すべてを表示
Insulet Corporation (PODD) 最新ニュース
No. 1 Medical Device Maker Insulet In 11 Stocks New To IBD Lists - Investor's Business Daily
Insulet stock hits 52-week high at $329.55 - Investing.com
Cisco, Rocket Companies, Insulet And More On CNBC's 'Final Trades' - Benzinga
Insulet Corp to Present at Upcoming Investor Conferences Amidst Diabetes Management Focus - AInvest
Why This IBD Stock Of The Day Just Broke Out — Again - Investor's Business Daily
Final Trades: Rocket Companies, Cisco Systems, Insulet Corp and the IGV - MSN
Insulet to Participate in Upcoming Investor Conferences - Business Wire
Insulet Corporation : There is still some upside potential - MarketScreener
Is Insulet Corporation subject to activist investor interest2025 Market WrapUp & AI Powered Trade Plan Recommendations - thegnnews.com
Insulet’s (PODD) Aggressive Revenue Guidance and Buyback Might Change the Case for Investing - simplywall.st
Published on: 2025-08-16 12:18:14 - sundaytimes.kr
Insulet Shares Soar on Volume Surge as Stock Ranks 495th in Market Activity for the Day - AInvest
Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Catalysts & High Accuracy Trade Signal Alerts - newsyoung.net
Short Covering May Lift Insulet Corporation in Near TermQuarterly Profit Review & Weekly High Return Opportunities - sundaytimes.kr
Stock Market Today: Indexes Hold Strong, But Small Caps Lag; Netflix, Amazon, Insulet In Focus - Investor's Business Daily
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings - simplywall.st
Insulet's (NASDAQ:PODD) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Investors Can Find Comfort In Insulet's (NASDAQ:PODD) Earnings Quality - 富途牛牛
The Top 5 Analyst Questions From Insulet’s Q2 Earnings Call - Yahoo Finance
Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD) - Seeking Alpha
Elliott Wave Theory Predicts Pullback in Insulet CorporationEarnings Miss & Intraday High Probability Setup Alerts - beatles.ru
Sapiens International Q2 Earnings Decline, Revenue Rises Amid Acquisition Deal - AInvest
PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - Yahoo Finance
Insulet Rises to 470th in Trading Volume as Q2 Revenue Surges 32.9 and Margins Expand - AInvest
Insulet Q2 Earnings and Revenue Exceed Estimates, Stock Rises, Margins Improve - AInvest
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - TradingView
Insulet Corporation Reports Strong Q2 2025 Growth - MSN
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest
Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st
Is It Too Late to Sell Insulet CorporationLow Drawdown Real Time Trading Tips Shared - beatles.ru
Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest
Insulet’s Earnings Call Highlights Robust Growth and Optimism - The Globe and Mail
Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛
RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest
Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest
Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st
Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener
Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada
Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria
RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener
Insulet price target raised to $350 from $330 at RBC Capital - TipRanks
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital - StreetInsider
Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript - Insider Monkey
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group - StreetInsider
Insulet price target raised to $353 from $331 at Canaccord - TipRanks
Morgan Stanley Raises Price Target on Insulet to $370 From $355, Keeps Overweight Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $399 From $380, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $353 From $331, Maintains Buy Rating - MarketScreener
Insulet Corporation (PODD) 財務データ
収益
当期純利益
現金流量
EPS
Insulet Corporation (PODD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Singh Prem | SVP, Global Operations |
Aug 07 '25 |
Sale |
320.00 |
1,343 |
429,760 |
4,143 |
1.77%
大文字化:
|
ボリューム (24 時間):